MetaCap

Amylyx Pharmaceuticals Balance Sheet

NASDAQ: AMLXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

28.14+0.94 (+3.46%)

At close: Oct 9, 4:00 PM ET · Delayed 15 min

Amylyx Pharmaceuticals financial position

At the end of fiscal 2025, Amylyx Pharmaceuticals reported total assets of $332.6 million, up 71.8% from a year earlier against total liabilities of $27.4 million. Shareholders' equity stood at $305.3 million, or 91.8% of assets. The company held $226.7 million in cash and equivalents.

The current ratio (current assets divided by current liabilities) was 14.27, meaning short-term assets cover obligations due within a year.

Summary generated from market data by MetaCap's automated system. Methodology

Amylyx Pharmaceuticals balance sheet (annual)

Amylyx Pharmaceuticals annual balance sheet
Fiscal year (USD)FY 20252025-12-31FY 20242024-12-31FY 20232023-12-31FY 20222022-12-31FY 20212021-12-31
Cash & Equivalents226.65M77.39M170.20M62.53M50.19M
Short-Term Investments90.33M99.11M201.16M284.42M45.93M
Receivables88.00K447.00K40.05M15.31M—
Inventory——38.32M9.77M—
Total Current Assets323.67M189.43M464.67M382.13M104.95M
Property, Plant & Equipment310.00K961.00K2.69M2.61M474.00K
Total Assets332.64M193.63M517.45M391.45M105.61M
Accounts Payable3.52M2.94M22.06M6.26M4.37M
Total Current Liabilities22.69M28.41M82.04M46.61M17.40M
Total Liabilities27.39M28.87M84.02M50.85M17.43M
Shareholders' Equity305.26M164.76M433.43M340.61M-151.17M
Retained Earnings-751.43M-606.69M-304.95M-354.22M-155.84M
Net Cash (Debt)316.98M176.50M371.36M346.94M96.12M
Shares Outstanding109.88M68.63M67.71M66.51M7.02M

This table shows 5 annual periods of Amylyx Pharmaceuticals's balance sheet, from FY 2025 back to FY 2021, across 14 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow AMLX's reporting calendar. What is a balance sheet?

More financial data